Table 2 Comparison between the patients with Vs < 1.55 m/s and those with Vs ≧ 1.55 m/s in all the 231 patients
From: PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients
Patients with Vs ≧ 1.55 m/s | Patients with Vs < 1.55 m/s | Comparison between patients with Vs < 1.55 m/s and those with Vs ≧ 1.55 m/s | Multiple regression analysis for factors associated with ≧ 1.55 m/s | ||
|---|---|---|---|---|---|
(n = 117) | (n = 114) | Odds ratio (95% confidence interval) | p | ||
Age (yrs) | 66.1 ± 10.0 | 60.0 ± 11.6 | p < 0.0001 | 1.06 (1.03 - 1.09) | p < 0.0001 |
Gender (male/female) | 51/66 | 52/62 | NS | NS | |
BMI (kg/m2) | 23.0 ± 3.7 | 22.0 ± 3.2 | p = 0.0281 | 1.12 (1.03 - 1.22) | p = 0.0082 |
Response to IFN treatment (NVR/no past IFN therapy) | 45/72 | 49/65 | NS | ||
PNPLA3 (GG/CC・CG) | 27/90 | 14/100 | p = 0.0318 | 2.07 (0.97 - 4.42) | p = 0.0599 |
AST (IU/L) | 70.2 ± 47.3 | 42.4 ± 46.4 | p < 0.0001 | ||
ALT (IU/L) | 74.0 ± 79.0 | 50.64 ± 71.3 | p = 0.0195 | ||
γ-GTP (IU/L) | 61.2 ± 50.2 | 56.4 ± 100.4 | NS | ||
Albumin (g/dL) | 3.8 ± 0.7 | 4.4 ± 0.4 | p < 0.0001 | ||
Total bilirubin (mg/dL) | 1.03 ± 0.56 | 0.87 ± 1.05 | NS | ||
Platelet count (x104/μL) | 10.7 ± 4.4 | 16.3 ± 5.2 | p < 0.0001 | ||
Prothrombin time (%) | 88.0 ± 14.8 | 101.2 ± 20.0 | p < 0.0001 | ||
Hyaluronic acid (ng/mL) | 348.1 ± 330.7 | 123.0 ± 306.7 | p < 0.0001 | ||
α-fetoprotein (ng/mL | 146.0 ± 726.0 | 5.30 ± 5.2 | p = 0.0452 | ||
PIVKA-II(mAU/mL) | 29.3 ± 29.8 | 20.0 ± 10.9 | p = 0.0023 | ||
HCV genotype (1/2/3) | 101/14/2 | 87/27/0 | p = 0.0283 | NS | |
HCV RNA (log IU/mL) | 6.2 ± 0.9 | 6.1 ± 1.1 | NS | ||
Velocity of shear wave (m/s) | 1.98 ± 0.46 | 1.27 ± 0.26 | p < 0.0001 | ||
Hepatocellular carcnoma (present/absent) | 42/75 | 6/108 | p < 0.0001 | ||